von Fallois, Moritz
Kosyna, Friederike Katharina
Mandl, Markus
Landesman, Yosef
Dunst, Jürgen
Depping, Reinhard http://orcid.org/0000-0002-4860-6058
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (KO5512/2-1)
Universität zu Lübeck
Universität zu Lübeck
Article History
Received: 13 January 2021
Accepted: 30 March 2021
First Online: 15 April 2021
Declarations
:
: Yosef Landesman is Senior Director and Head of Biology and Scientific Affair at Karyopharm Therapeutics Inc. and holds patents, equity and stocks and has received both major and minor remunerations from Karyopharm. The authors report no other conflicts of interest in this work.